Those with severe melanomas who received the vaccine and Merck's cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda, the biotech companies said in a news release.
The results are a vindication of sorts for Moderna's strategy to develop new uses for messenger RNA technology used in its COVID-19 vaccine.
[
add
]
[
|
|
...
]